Recurrent implantation failure
Conditions
Interventions
LGTB treatment group:1-month regimen of three times weekly rifapentine (150mg per capsule, 450mg po tiw) plus isoniazid (100mg per tablet, 400mg po tiw)
LGTB no treatment group:take no medication related to preventive treatment of tuberculosis
non-LGTB group:take no medication related to preventive treatment of tuberculosis
Sponsors
Shanghai First Maternity and Infant Hospital
Eligibility
Sex/Gender
Female
Age
25 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Female, age = 25 years old and = 40 years old; 2. Patients with 3 or more failed embryo implantation (or more than 4 high-quality embryos transferred); 3. Patients with IVF / ICSI in accordance with conventional IVF indications, including tubal pelvic factors and male factors; 4. In patients with normal uterine cavity by ultrasound or HSG, the endometrium on the day of previous transplantation was = 8mm; 5. Patients who voluntarily join the study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. The patients with uterine malformation and intrauterine adhesions had endometrial polyps and hydrosalpinx; 2. The patients with abnormal karyotype were identified; 3. Using donor sperm or egg; 4. Patients with active tuberculosis; 5. In the past two years, patients who have received full course anti tuberculosis treatment due to active tuberculosis, or who have taken rifamycin (rifampicin, rifampicin, etc.) for more than 14 days due to active tuberculosis; 6. Patients who are allergic or intolerant to rifamycin (rifapentine or rifampicin); 7. HIV antibody test positive and AIDS patients; 8. Patients with abnormal liver function: total bilirubin > 2.5 mg / dl (43 umol / L), AST or ALT more than twice the normal upper limit value; 9. Patients who are receiving immunosuppression and biological agents treatment; 10. Patients with diabetes mellitus; 11. There are other serious physical or psychological diseases that are not suitable for the selection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate;Ongoing Pregnancy Rate;Miscarriage rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Implantation rate;Incidence of LGTB;ectopic pregnancy rate;Incidence of grade 3 or greater adverse events;Discontinuation of treatment due to side effect of study drugs;Discontinuation of treatment;Completion rate of preventive treatment;Incidence of FGTB; | — |
Countries
china
Contacts
Public ContactXiaoming Teng
Shanghai first maternal and infant health care hospital
Outcome results
None listed